Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€5.21

€5.21

-1.060%
-0.056
-1.060%
€12.21

€12.21

 
22:26 / Tradegate WKN: A1180P / Symbol: OCUL / Name: Ocular / Stock / Healthcare Equipment & Supplies / Small Cap /
Latest predictions
€13.03
08.05.24
-2.51%
buy
06.04.24
-36.43%
16.03.24
-39.09%
10.03.24
-43.45%
€13.83
26.02.24
-44.56%
buy
18.02.24
-27.48%
Best running prediction
€11.40
04.10.23
88.28%
buy
Your prediction

Ocular Therapeutix Inc. Stock

We can see a decrease in the price for Ocular Therapeutix Inc.. Compared to yesterday it has lost -€0.056 (-1.060%).
Currently there is a rather positive sentiment for Ocular Therapeutix Inc. with 8 Buy predictions and 5 Sell predictions.
With a target price of 12 € there is potential for a 130.15% increase which would mean more than doubling the current price of 5.21 € for Ocular Therapeutix Inc..
So far the community has only identified positive things for Ocular Therapeutix Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Ocular Therapeutix Inc. in the next few years

Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Ocular Therapeutix Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Ocular Therapeutix Inc. -1.060% -8.170% -30.016% -8.042% 25.357% -59.538% 62.396%
Orasure Tech -1.270% -8.627% -12.897% -29.925% -37.450% -40.272% -41.065%
scPharmaceuticals -0.920% -2.262% -7.692% -55.918% -24.870% -8.475% -
SI-BONE Inc 4.380% 5.926% -0.694% -31.905% -24.737% -42.800% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-18

Ocular Therapeutics, Inc., trading under the US symbol OCUL, operates in the Healthcare Equipment & Supplies industry. Upon observing the company's financial statements, it seems that Ocular Therapeutics is not generating enough profitability. However, their financial health has shown some fluctuations over the years. In the following analysis, the financial aspects of Ocular Therapeutics will be examined thoroughly, revealing the potential strengths and weaknesses in the company's financial position.

Rising Revenue: The total revenue of Ocular Therapeutics has been increasing year-on-year. Between 2020 and 2022, the company's total revenue grew from $17.4 million to $51.49 million. This shows that the company has been successful in boosting its sales, which is a positive indication for future growth.

Research & Development Investment: Ocular Therapeutics has consistently devoted a significant portion of its expenditure to research and development activities. The research and development expenses have increased from $28.69 million in 2020 to $53.46 million in 2022. This demonstrates the company's commitment to innovation and product improvement, which could lead to better market positioning and long-term growth prospects.

Comments

Prediction Buy
Perf. (%) -2.51%
Target price 13.027
Change
Ends at 08.05.25

Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target lowered by analysts at HC Wainwright from $16.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for OCUL provided by MarketBeat
Show more

Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for OCUL provided by MarketBeat
Show more

Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for OCUL provided by MarketBeat
Show more